Who
Amy W. Schulman
Director
Company insider
Files Form 4 as: Director, Alnylam Pharmaceuticals; Director, Elevance Health; Director, Fractyl Health; Director and 10% owner, SQZ Biotechnologies Co; Director, Hudson Executive Investment Corp. II; Director, Cyclerion Therapeutics; Director, Ironwood Pharmaceuticals; Director, X4 Pharmaceuticals.
In numbers
- Trades disclosed
- 181
- Buys
- 5
- Sells
- 5
- Bought
- $14.2M
- Sold
- $9.9M
- Companies
- 12
- Companies where not an officer
- 11
- First trade
- 30 Jun 2008
- Last trade
- 20 May 2026
- Last filed
- 22 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 May 2026filed 22 May 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —838 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,802 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,802 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —838 at $0.00 | filing |
| 13 May 2026filed 15 May 2026 | ELV Elevance HealthManaged Care & Insurers | SEC FORM 4 Code A | —563 at $0.00 | filing |
| 13 May 2026filed 15 May 2026 | ELV Elevance HealthManaged Care & Insurers | SEC FORM 4 Code A | —563 at $0.00 | filing |
| 13 May 2026filed 14 May 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $790K11,250 at $70.20 | filing |
| 13 May 2026filed 14 May 2026 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,250 at $0.00 | filing |
| 13 May 2026filed 14 May 2026 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,250 at $0.00 | filing |
| 13 May 2026filed 14 May 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $790K11,250 at $70.20 | filing |
| 12 Mar 2026filed 23 Mar 2026 | ELV Elevance HealthManaged Care & Insurers | SEC FORM 4 Sold | $7,47526 at $287.50 | filing |
| 12 Mar 2026filed 23 Mar 2026 | ELV Elevance HealthManaged Care & Insurers | SEC FORM 4 Sold | $7,47526 at $287.50 | filing |
| 2 Feb 2026filed 3 Feb 2026 | ELV Elevance HealthManaged Care & Insurers | SEC FORM 4 Code A | —218 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | ELV Elevance HealthManaged Care & Insurers | SEC FORM 4 Code A | —218 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | GUTS Fractyl Healthoption or derivative · Medical Devices | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 8 May 2025filed 12 May 2025 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,558 at $0.00 | filing |
| 8 May 2025filed 12 May 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —775 at $0.00 | filing |
| 13 Mar 2025filed 17 Mar 2025 | GUTS Fractyl HealthMedical Devices | SEC FORM 4 Bought | $10K8,550 at $1.17 | filing |
| 13 Mar 2025filed 14 Mar 2025 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,750 at $0.00 | filing |
| 13 Mar 2025filed 14 Mar 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $361K2,750 at $131.21 | filing |
News
Elevance Health reaches $425.27, completing a full-year round tripELV · 247wallst.com · 14 Oct 2026Elevance Health (NYSE:ELV) Given New $460.00 Price Target at GuggenheimELV · themarketsdaily.com · 13 Oct 2026
0 headlines in the last 90 days name Amy W. Schulman; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.